Anti-interleukin-5 therapy (mepolizumab) in life-threatening asthma attack: A case-based discussion.

• 发表时间: 2019
• 来源期刊: Respir Med Case Rep
• DOI: 10.1016/j.rmcr.2019.100927
• PMID: 31485410
• 文章类型: Case Reports
• 作者列表: Tello K,Hoffmann A,Beutel B,Greulich T,Vogelmeier CF,Richter MJ,Kuhnert S,Böselt T,Alter P,Holland A,Idzko M,Buhl R,Koczulla AR

关键词: Anti-IL-5-therapy; Asthma; Eosinophilia; Exacerbation; Intensive care medicine

Abstract

We report about a case of a compassionate off-label use of the anti-interleukin-5-agent mepolizumab in a ventilated patient with life-threatening asthma attack in eosinophilic asthma. The patient suffered from severe eosinophilic asthma and was transmitted to our hospital with an asthma attack and a life-threatening respiratory state under ventilation. Since high dose steroids had not yielded a sufficient respiratory improvement mepolizumab was administered subcutaneously. After administration of mepolizumab respiratory state and ventilation parameter improved significantly. Two days after administration the patient was weaned could be extubated 8 days later and recovered completely from the asthma attack. The presented clinical case is suggestive of future clinical trials or registry studies to evaluate potential clinical benefits of anti-interleukin-5 treatment in patients with severe exacerbations of eosinophilic asthma.